|
NCT04346147
|
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 |
Active, not recruiting |
Phase 2 |
May/07/2020 |
Sep/01/2021 |
- Alternative id - 24032020
- Interventions - Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet|Other: Supportive tratment
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 168
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - time to clinical improvement|Safety of treatments|Tolerability of treatments
|
|
NCT04422678
|
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia |
Not yet recruiting |
Phase 3 |
Jun/01/2020 |
Oct/01/2020 |
- Alternative id - Alex CCM 2020/5
- Interventions - Drug: Imatinib Mesylate|Drug: Standard of Care
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Primary endpoint: Disease Progression|Improvement in Hypoxic Index|Hospital Length of Stay|Days on invasive mechanical ventilation|Inflammatory Markers|Viral clearance|Radiological assessment|Safety of Imatinib
|
|
NCT05220280
|
SOLIDARITY Finland Plus Long COVID-19 |
Not yet recruiting |
Phase 4 |
Feb/06/2022 |
Dec/01/2025 |
- Alternative id - SOLP21
- Interventions - Drug: Imatinib|Drug: Infliximab
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 400
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Long-COVID symptoms|Health-related quality of life|Mortality|Incidence of comorbidity|Lung function|Whole-genome sequencing
|
|
NCT04953052
|
A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care. |
Recruiting |
Phase 2 |
Nov/01/2021 |
Apr/01/2022 |
- Alternative id - EX003|959310
- Interventions - Drug: Imatinib Mesylate|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Sir Sayajirao General Hospital (SSG Hospital), Medical College Baroda, Jail Road Indira Avenue)Anandpura, Vadodara, Gujarat, India|St George's Hospital, P D Mello Road, Fort Road, CST Terminal,, Mumbai, Maharashtra, India|Government Medical College and Hospital, Nagpur, Maharashtra, India|PCMC PGI Yashwantrao Chavan Memorial Hospital, Nagar, Pune, India|NRS Medical College and Hospital, Kolkata, West Bengal, India|Father Muller Hospital and Medical College, Mangalore, India|JSS Hospital, Mysuru, India|Indira Gandhi Government Medical College and Hospital, Nagpur, India
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 84
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change from baseline in Oxygen Saturation Index (OSI) at Day 10|Change from Baseline in Oxygen Saturation Index (OSI) at Day 3 and Day 5|Mortality rate at Day 29 and Day 60|Change from baseline in WHO 9-point ordinal scale for clinical improvement to Day 10 and Day 29|Duration of mechanical ventilation (Days) to Day 29 and Day 60|Duration of stay in ICU (Days) to Day 29 and Day 60|Time to first successful extubation (Hours) to Day 29|Number of days free of mechanical ventilation and survival (VFDsurv) at Day 29 and Day 60
|
|
NCT04394416
|
Trial of Imatinib for Hospitalized Adults With COVID-19 |
Recruiting |
Phase 3 |
Jun/02/2020 |
Jun/01/2023 |
- Alternative id - 2038GCCC
- Interventions - Drug: Imatinib|Drug: Placebo oral tablet
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Maryland Medical Center, Baltimore, Maryland, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 204
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events
|
|
NCT04794088
|
Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients |
Recruiting |
Phase 2 |
Mar/14/2021 |
Feb/01/2022 |
- Alternative id - INVENT COVID
- Interventions - Drug: Imatinib Mesylate intravenous solution|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Amsterdam Universitair Medische Centra, location VUmc, Amsterdam, Noord-Holland, Netherlands|Amsterdam Universitair Medische Centra, location AMC, Amsterdam, Noord-Holland, Netherlands
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 90
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in extravascular lung water index|Pulmonary vascular permeability|PaO2/FiO2 ratio as measure of gas-exchange|Oxygenation index as measure of gas-exchange|Driving pressure as an indicator of global lung strain|Compliance as a measure of respiratory mechanics|Mechanical power as quantification of the energy load delivered to the lung per positive pressure breath|Pro-inflammatory cytokines|Matrix metalloproteinases as markers of inflammation|D-dimer as an inflammatory biomarker|Angiopoietin-1 and -2 as biomarkers of endothelial activation and injury|Soluble thrombomodulin as a biomarker of endothelial activation and injury|Surfactant as biomarker of lung epithelial injury|Protein biomarkers of lung epithelial injury|SOFA score as organ function and outcome measure|WHO ordinal scale for clinical improvement as functional outcome measure|Morbidity and mortality outcomes|28-day mortality|Hemoglobin cell count as drug safety parameter|Blood cell count as drug safety parameter|Serum creatinine as measure of kidney function|Estimated glomerular filtration rate as measure of kidney function|Electrolytes as drug safety parameters|Liver enzymes as drug safety parameter|Serum bilirubin as drug safety parameter|NT-proBNP as drug safety parameter|Reporting of adverse and serious adverse events|Corrected QT interval on ECG|Total concentration as a pharmacokinetic measure of imatinib|Free fraction as a pharmacokinetic measure of imatinib|Imatinib metabolite AGP|Imatinib metabolite albumin|Thoracic ultrasound
|
|
NCT04357613
|
IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. |
Not yet recruiting |
Phase 2 |
Sep/01/2020 |
Dec/01/2021 |
- Alternative id - P20/05_IMAGE19
- Interventions - Drug: Experimental drug
- Study type - Interventional
- Study results - No Results Available
- Locations - CHU Bordeaux, Bordeaux, France|CH de Versailles, Le Chesnay, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 99
- Age - 70 Years and older (Older Adult)
- Outcome measures - To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.|To evaluate the feasibility of imatinib therapy.|To evaluate safety of imatinib therapy|To evaluate the clinical evolution|To evaluate the progression rate to severe COVID-19 disease|To evaluate mortality|To evaluate viral load|To evaluate plasmatic levels of imatinib
|
